The estimated Net Worth of James E Deerfield Mgmt Iii,... is at least $3.61 million dollars as of 8 February 2016. James Iii owns over 100,000 units of Editas Medicine Inc stock worth over $3,608,766 and over the last 9 years James sold EDIT stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Iii EDIT stock SEC Form 4 insiders trading
James has made over 1 trades of the Editas Medicine Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently James bought 100,000 units of EDIT stock worth $1,600,000 on 8 February 2016.
The largest trade James's ever made was buying 100,000 units of Editas Medicine Inc stock on 8 February 2016 worth over $1,600,000. On average, James trades about 100,000 units every 0 days since 2016. As of 8 February 2016 James still owns at least 954,700 units of Editas Medicine Inc stock.
You can see the complete history of James Iii stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Editas Medicine Inc
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr et Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
What does Editas Medicine Inc do?
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
What does Editas Medicine Inc's logo look like?
Complete history of James Iii stock trades at Editas Medicine Inc
Editas Medicine Inc executives and stock owners
Editas Medicine Inc executives and other stock owners filed with the SEC include:
-
Cynthia Collins,
President, Chief Executive Officer, Director -
Charles Albright,
Executive Vice President, Chief Scientific Officer -
Dr. Bruce E. Eaton Ph.D.,
Exec. VP & Chief Bus. Officer -
Michelle Robertson,
CFO, Principal Accounting Officer, Treasurer & Assistant Sec. -
David Scadden,
Independent Director -
James Mullen,
Independent Chairman of the Board -
Jessica Hopfield,
Independent Director -
Andrew Hirsch,
Independent Director -
Dr. Lisa A. Michaels M.D.,
Exec. VP & Chief Medical Officer -
Akshay Vaishnaw,
Independent Director -
James C. Mullen,
Chairman, Pres & CEO -
Lisa Michaels,
Executive Vice President, Chief Medical Officer -
Mark Mullikin,
Investor Relations Officer -
Gad Berdugo,
Chief Business Officer -
Harry Gill,
Senior Vice President - Operations -
Michelle Robertson,
Chief Financial Officer -
Dr. Gilmore O'Neill,
Pres & CEO -
Charlene Stern J.D., Ph.D.,
Exec. VP & Gen. Counsel -
Ron Moldaver,
Investor Relations -
Dr. J. Keith Joung M.D., Ph.D.,
Co-Founder & Scientific Advisory Board Member -
Dr. George McDonald Church Ph.D.,
Co-Founder & Scientific Advisory Board Member -
Charlene Stern,
Sr. VP & Chief Legal Officer -
Dr. Mark S. Shearman,
Exec. VP & Chief Scientific Officer -
Harry R. Gill III,
Sr. VP of Operations -
Dr. David R. Liu,
Co-Founder & Scientific Advisory Board Member -
Dr. J. Keith Joung,
Co-Founder & Scientific Advisory Board Member -
Dr. George M. Church,
Co-Founder & Scientific Advisory Board Member -
Dr. Feng Zhang,
Co-Founder & Scientific Advisory Board Member -
Douglas G. Cole,
Director -
Katrine Bosley,
President and CEO -
Kevin P Starr,
10% owner -
Alexis Borisy,
Director -
Alexandra Glucksmann,
Chief Operating Officer -
Venture Management Co. Vi, ...,
-
Ventures Fund Iv, L.P.Flags...,
-
Kevin Bitterman,
Director -
Gerald Frank Cox,
Chief Medical Officer -
Ventures Fund Iv, L.P.Flags...,
-
John Mendlein,
Director -
Boris Nikolic,
Director -
Andrew A. F. Hack,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Llc Bng0,,
10% owner -
Bernadette Connaughton,
Director -
Elliott M. Levy,
Director -
Vickesh Myer,
Chief Technology Officer -
Global Investors Lp Viking ...,
-
Global Performance Llc Viki...,
-
James E Deerfield Mgmt Iii,...,
-
Baisong Mei,
EVP, CHIEF MEDICAL OFFICER -
Mark S Shearman,
EVP, CHIEF SCIENTIFIC OFFICER -
Meeta Chatterjee,
Director -
Bruce Eaton,
EVP, CBO AND CTO -
Emma Reeve,
Director -
Erick Lucera,
EVP, CHIEF FINANCIAL OFFICER -
Gilmore Neil O'neill,
CEO -
Linda Burkly,
EVP, CHIEF SCIENTIFIC OFFICER